Loading stock data…
Madrigal Pharmaceuticals, Inc. (MDGL)
$541.08-1.53 (-0.28%)
Pre-Market$541.00-0.08 (-0.01%)· Last close Sep 4
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Madrigal Pharmaceuticals, Inc. in the Healthcare sector is trading at $534.16 with a market capitalization of $11.7B. Wall Street consensus targets $678.06 (16 analysts), implying a +26.9% move over the next 12 months. The stock is currently 13% below its 52-week high of $615.00, remaining 3.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +26.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $364.25M↑ | $311.34M↓ | $321.08M↑ | $287.27M↑ | $212.80M |
| Gross Profit | $324.25M↑ | $284.49M↓ | $296.63M↑ | $269.15M↑ | $203.74M |
| Operating Income | -$56.31M↑ | -$92.72M↓ | -$59.61M↑ | -$113.97M↓ | -$47.20M |
| Net Income | -$57.94M↑ | -$94.39M↓ | -$58.58M↑ | -$114.19M↓ | -$42.28M |
Peer Comparison
JNJUNHPFE
Fundamentals
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor bet...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.73B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-62.07%
Volume
Today's trading volume
177,171
Recent News
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
Rezdiffra's biggest growth opportunity may still be ahead.
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
Madrigal Pharmaceuticals (NASDAQ:MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts. Speaking at a Canaccord Genuity event, C
Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls
Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More
Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at some of the market's biggest names with fresh upgrades, downgrades, and new coverage that could reshape how investors approach the week ahead.
Madrigal Pharmaceuticals (MDGL) Beat Earnings Estimates, Is It Still Below Fair Value?
Madrigal Pharmaceuticals (MDGL) drew attention after its second quarter 2026 earnings release, which highlighted Rezdiffra sales growth, stronger patient uptake, a smaller than expected quarterly loss, and revenue ahead of market estimates. See our latest analysis for Madrigal Pharmaceuticals. Despite solid interest in Rezdiffra and pipeline updates, Madrigal Pharmaceuticals’ share price has slipped recently, with the 30 day share price return down 8.16% and the year to date share price...